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Iron Overload Cardiomyopathy
Better Understanding of an Increasing Disorder
Pradeep Gujja, MD,* Douglas R. Rosing, MD,† Dorothy J. Tripodi, RN,†
Yukitaka Shizukuda, MD, PHD*†
Cincinnati, Ohio; and Bethesda, Maryland
The prevalence of iron overload cardiomyopathy (IOC) is increasing. The spectrum of symptoms of IOC is varied.
Early in the disease process, patients may be asymptomatic, whereas severely overloaded patients can have
terminal heart failure complaints that are refractory to treatment. It has been shown that early recognition and
intervention may alter outcomes. Biochemical markers and tissue biopsy, which have traditionally been used to
diagnose and guide therapy, are not sensitive enough to detect early cardiac iron deposition. Newer diagnostic
modalities such as magnetic resonance imaging are noninvasive and can assess quantitative cardiac iron load.
Phlebotomy and chelating drugs are suboptimal means of treating IOC; hence, the roles of gene therapy, hepci-
din, and calcium channel blockers are being actively investigated. There is a need for the development of clinical
guidelines in order to improve the management of this emerging complex disease. (J Am Coll Cardiol 2010;
56:1001–12) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.083t
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dron is an essential element that forms an important
omponent of metabolic and biological processes, but when
resent in excess, it can produce tissue damage due to
xidative stress (1). Excess body iron may accumulate in
iver, spleen, heart, bone marrow, pituitary, pancreas, and
he central nervous system, causing damage to these organs.
ron overload cardiomyopathy (IOC) results from the ac-
umulation of iron in the myocardium, and it is the leading
ause of death in patients receiving chronic blood transfu-
ion therapy (2). The incidence of IOC is increasing
orldwide, and it is usually managed by cardiologists.
oteworthy has been its increase in individuals with hema-
ologic malignancies, especially with the increased use of
reatments such as bone marrow transplant and stem cell
herapy (3). Furthermore, as patients with sickle cell disease
nd thalassemia live longer, IOC incidence rises. It has been
ocumented that adequate medical therapy can reverse IOC
hen it is diagnosed before end-stage heart failure occurs
4), thus underscoring the importance of early detection of
OC. Thus, it is critical for cardiology care providers to keep
heir knowledge updated on managing IOC to take advan-
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010, accepted March 18, 2010.age of recent progress in this area. In this paper, the current
tatus of diagnosis of IOC, particularly using imaging
odalities and updated therapeutic approach for IOC, is
eviewed.
tiology
OC has been defined as the presence of systolic or diastolic
ardiac dysfunction secondary to increased deposition of
ron in the heart independent of other concomitant pro-
esses (1). Excess iron accumulation in the body usually
akes place either by increased gastrointestinal (GI) iron
bsorption (hemochromatosis) or excess administration of
xogenous iron by dietary sources or red blood cell (RBC)
ransfusions (hemosiderosis). These conditions are de-
cribed in Table 1.
ncreased iron absorption. Hereditary hemochromatosis
HH) is an autosomal disorder in which mutations of specific
enes involved in iron metabolism cause iron overload in the
ody, with increased GI absorption (5,6). It has been divided
nto 4 subtypes as described in Table 1. The association of IOC
ith HH has been well characterized (7,8). Increased GI
bsorption with a normal diet is also observed in porphyria
utanea tarda (9); chronic liver disease, including nonalcoholic
atty liver disease (10); hepatitis B (11) or C (12); and in
neffective erythropoiesis, as seen in sideroblastic anemia (13)
nd severe thalassemia (14).
xcess administration of exogenous iron. Sub-Saharan
fricans have a high dietary iron intake as a result of
rinking traditional beers fermented in steel drums (African
ron overload) (15). This mechanism of iron overload was
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ogy of hepatic carcinoma and
cardiomyopathy in these pa-
tients, but other reports suggest
that environmental factors super-
imposed on genetic predisposi-
tion may be a better explanation
for the development of these
conditions (16,17).
Parenteral iron administration.
Chronic blood transfusion is the
cornerstone of treatment for he-
reditary anemias such as thalas-
semia and sickle cell disease. A
unit of packed RBCs consists of
200 to 250 mg of elemental iron
that accumulates in the body be-
cause there is no active excretion
of iron. Over long periods of
repeated transfusions, iron over-
load occurs with deposition of
ron in multiple organs. Earlier detection of these hereditary
nemias is associated with a decreased mortality due to
mproved treatment, but treatment often requires persistent
hronic transfusion, one of the reasons for an increasing
ncidence of iron overload (18–20).
athogenesis
ron kinetics is illustrated in Figure 1 (21–23). Deposition
f iron in the heart is a gradual process and depends on the
ncreasing levels of serum iron. Under normal iron ho-
eostasis, cardiac iron is regulated through transferrin-
ediated uptake mechanisms. During iron overload, trans-
errin is saturated, and nontransferrin-bound iron is released
nto the circulation and enters cardiac myocytes in the
errous form through L-type calcium channels (LTCC) as
as been described (24). Endosome-mediated uptake might
lso play a role, but is poorly understood (25). Iron is then
ound to ferritin and transported to lysosomes for degrada-
ion and long-term storage in the cardiac myocyte (25).
athologic iron deposition begins initially within the epi-
ardium and extends to the myocardium and then the
ndocardium, which helps explain the preservation of sys-
olic function until very late in the disease (1). Once the
ntioxidant capacity of the cell is exceeded, iron is catalyzed
y the rapid Fenton reaction producing hydroxyl ions,
hich is an extremely reactive free radical species that causes
ipid peroxidation producing membrane permeability alter-
tions. These modifications create a leak of hydrolytic
nzymes that initiate cell damage and subsequent cardiac
yocyte death. In cases with concomitant myocardial isch-
mia, iron overload can accelerate ischemia-induced reper-
usion injury, and may lead to an autocatalytic process that
esults in a cardiomyopathic process (1,26). Initial evidence
Abbreviations
and Acronyms
CC  calcium channel
blocker
CT  computed
tomography
GE  gradient echo
GI  gastrointestinal
HH  hemochromatosis
IOC  iron overload
cardiomyopathy
LTCC  L-type calcium
channel
LV  left ventricular
MRI  magnetic resonance
imaging
RBC  red blood cell
SE  spin echo
TE  echo timeuggests that deposition of iron in the sarcoplasm of lpicardial myocytes in this disease is a problem of storage and
s not an infiltrative process. Thus, there is the potential for the
ron to be removed and for the process to be reversed, which
as been the subject of much investigation and has influenced
he direction therapeutic interventions have followed (27).
linical Presentation
ecause of the wide spectrum of etiologies for IOC,
ymptoms may be quite varied. Early in the disease process,
atients may be totally asymptomatic, whereas severely
verloaded patients can have terminal irreversible heart
ailure symptoms. Thus, early identification of the dis-
ase becomes a very important consideration. Multiple
hysiologic, biomolecular, and structural factors such as
achycardia, volume overload, eccentric left ventricular (LV)
ypertrophy, endocrinopathies, genetic predisposition, neu-
ohormonal activation, and proinflamatory cytokines can
lay a role in affecting cardiac function (4,28,29). Patients’
nitial presentation is often exertional shortness of breath as
result of LV diastolic dysfunction secondary to a restrictive
athophysiology. This condition may later progress to a
ilated cardiomyopathy with LV systolic dysfunction
26,30,31). Iron accumulation occurs in the ventricular
yocardium before the atrial myocardium (25). Deposition
n the conduction system has also been noted (32) and can
ead to nodal disease causing bradyarrythmias and necessi-
ating pacemaker placement. First-degree AV blocks and
upraventricular arrhythmias correlate with the extent of
ron deposition in the atrial myocardium (33). Iron probably
s proarrythmic by itself (34), and this fact along with the
aried deposition of iron in the tissue, leading to nonho-
ogeneity in conduction velocity or repolarization, may
xplain the increased incidence of atrial and ventricular
achyarrhythmias that have been noted in subjects with iron
verload (35). Paroxysmal atrial fibrillation is the most
ommon form of arrhythmia seen in IOC and is invariably
ssociated with myocardial damage (4). LV dilation with
ystolic dysfunction predisposes to more frequent ventricular
rrhythmias. Moderate to severe LV dysfunction usually
ccurs with heavy iron deposition. Right heart failure can
lso be present early in the course of disease and be
ndependent of, or evolve and progress along with, left heart
ailure. With severe cardiac impairment, average survival is
sually1 year (26,33,36). Iron deposition can also occur in
he pericardium and, if extensive enough, result in clinical
igns and symptoms.
iagnosis
high degree of clinical suspicion is necessary to identify
nd categorize primary hemochromatosis and secondary
ron overload. Diagnosis can be very challenging in the early
tages of disease; an accurate assessment of organ-specific
ron overload is also helpful in planning treatment.
iochemical markers. To identify patients with iron over-oad, plasma transferrin saturation of 55% and serum
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September 21, 2010:1001–12 Review on Iron Overload Cardiomyopathyerritin of 200 ng/ml or 300 ng/ml (for women and men,
espectively) have been proposed as per the 2005 American
ollege of Physicians guidelines (37,38). However, trans-
errin saturation can miss a substantial population of pa-
ients who are homozygous for HFE mutations (39). It can
lso be elevated along with ferritin levels in Asian and
acific Islanders without the HFE mutations, and thus has
ncertain significance in these populations (40). Ferritin,
eing an acute-phase reactant (41), can be elevated in active
nflammatory conditions and also in certain liver diseases
42,43). Serum iron studies are a useful tool in screening
atients for total-body iron overload, but they are unsatis-
actory as a diagnostic tool to detect specific-organ overload
uch as cardiac iron. The level of serum ferritin at which
ron deposition is detected in the heart has not been defined.
here are reports of heavy cardiac iron deposition despite
he presence of low serum ferritin levels (44,45). Serum iron
tudies give little information on deposition of iron and less
n actual tissue location. In addition, serum ferritin levels in
tiology of Iron Overload DisordersTable 1 Etiology of Iron Overload Disorders
Disease Mechanism
Primary
Hereditary hemochromatosis
Type 1 (HFE related) (AR)
Increased GI absorption with normal diet
Type 2 (juvenile
hemochromatosis) (AR)
Increased GI absorption with normal diet
Type 3 (AR) Increased GI absorption with normal diet
Type 4 (AD) Increased GI absorption with normal diet
Secondary
a. Iron-loading anemias
(transfusion-related)
Thalassemia
Transfusion-related
In severe thalassemia, can have
increased GI absorption
Sickle cell anemia Transfusion-related
Sideroblastic anemia Transfusion-related
Increased GI absorption with
normal diet
Diamond-Blackfan anemia Transfusion-related
Congenital dyserythropoesis
anemia
Transfusion-related
Post-stem cell transplant patients Transfusion-related
Chronic kidney disease/end-stage
renal failure/dialysis
Oral and IV iron supplementation
Transfusion-related
b. Dietary overload
African iron overload
Increased dietary intake
c. Miscellaneous
Aceruloplasminemia (AR)
Congenital atransferrinemia (AR)
Chronic liver diseases
Hepatitis C and B
Alcohol-induced liver disease
Porphyria cutanea tarda
Fatty liver disease
Inhibition of iron oxidation
Inhibition of iron transportation
In part increased GI absorption
In part increased GI absorption
In part increased GI absorption
In part increased GI absorption
D  autosomal dominant; AR  autosomal recessive; GI  gastrointestinal; IV  intravenous.articular have a wide variability when measured serially, dhus making it difficult to use as a marker to determine
esponse to therapeutic interventions.
issue biopsy. Tissue biopsy is the traditional gold stan-
ard for making the diagnosis of liver iron overload (46), but
ron deposition in the heart tends to be patchy (33). Biopsies
ay thus miss the areas of deposition and provide a false
egative result. In myocardial biopsy specimens, the degree
nd cellular distribution of iron stores known as hemosid-
rin is best assessed using a Perls Prussian stain, and a
emiquantitative assessment of iron stores is derived based
n the number of myocytes containing stainable iron
27,47). In normal hearts, no stainable iron should be seen,
nd as iron overload progresses, the deposition of iron
ppears to occur in the sarcoplasm starting in the perinu-
lear areas and disseminating to the entire sarcoplasm
27,33,36,48). The iron concentration can be measured with
tomic absorption spectrometry, and Olson et al. (48) have
eported the average elemental iron in biopsy specimens are
99 g/g dry weight in normal subjects and 1,701 g/g
Molecular Correlate Iron Deposition
sense mutation
C282Y homozygosity
H63D homozygosity
C282Y/H63D heterozygosity
Other mutations of HFE
Liver, heart, endocrine glands
tation on HJV gene, which encodes for
hemojuvelin
e form where hepcidin is inactivated
Liver, heart, endocrine glands
tation of transferring receptor-2 Liver, heart, endocrine glands
tation of SLC40A1, which encodes for
erroportin
Macrophages, liver, heart,
endocrine glands
tation causing defect in synthesis of
- and -globin chains of hemoglobin
Heart, pancreas, pituitary,
liver
stitution of a valine for glutamic acid as the
6th amino acid on the beta globin chain (HbS)
Liver, heart
editary or acquired
ffective erythropoiesis
Neurons, heart, mitochondria
genital hypoplastic anemia with decreased
rythroid precursors
Heart, liver
ffective erythropoiesis Liver, heart, endocrine
Liver, heart
reased erythropoietin Heart, liver
reased diet with predisposing genetic factors
(proposed mechanism)
Heart, liver, endocrine
tations of ceruloplasmin gene
tations of transferrin gene
applicable
applicable
established, some are part AD
applicable
Liver, brain, pancreas
Liver, heart, pancreas
Liver
Liver
Liver
LiverMis
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Review on Iron Overload Cardiomyopathy September 21, 2010:1001–12verlap between these 2 groups. A positive result indicates
hat iron overload is present, but not how extensive the
rocess may be (27,36). Also, biopsy is an invasive proce-
ure and, as a result, is not an ideal tool to screen
symptomatic patients.
chocardiography. As iron overload proceeds, echocardi-
graphy may reveal biventricular dilation and progressive
vidence of a restrictive cardiomyopathy from myocardial
amage (49). Echocardiographic evidence of ventricular
iastolic dysfunction can be detected early before systolic
ysfunction occurs, specifically using tissue Doppler signals
50,51). Lambardo et al. (52) failed to identify diastolic
ysfunction using conventional Doppler echocardiographic
arameters such as mitral inflow E/A ratio and deceleration
ime to predict the severity of myocardial iron overload
erified by myocardial biopsy in thalassemia patients with
reserved LV systolic function. Later, however, Vogel et al.
53) reported that a decrease in peak systolic and peak
iastolic early-filling tissue Doppler wave is frequently seen
Figure 1 Iron Kinetics
Heme is absorbed by Heme carrier protein (HCP)-1 and released from iron by hem
is reduced by duodenal cytochrome b at the apical membrane of intestinal enteroc
(DMT)-1 (22,23). Ferrous iron is then transported to the basolateral portion of the
exporter Ferroportin (regulated by hepcidin) when there is a need for iron. Ferrous
loplasmin, Hephaestin, in intestinal cells to ferric iron and loaded on to transferrin
increases. Once the storage capacity is exceeded, metabolically active iron is rele
iron (NTBI).n the patients with -thalassemia and cardiac magnetic iesonance imaging (MRI)-proven myocardial iron overload,
nd that these declines are more prominent in the LV
eptum than lateral free wall. Tissue Doppler-derived peak
ystolic strain has similarly shown to decrease in that
opulation (54). Palka et al. (50) has reported a decrease
n peak systolic and diastolic early filling mitral annular
issue velocity as well as prolongation of the duration of
trial reversal wave of pulmonary vein Doppler in HH
atients with predominantly normal LV systolic function.
n our previous investigation in asymptomatic HH sub-
ects, echocardiography has detected enhanced left atrial
ctive contraction even before overt LV diastolic dysfunc-
ion appeared, and this may be the earliest detectable
chocardiographic finding of cardiac iron overload in this
opulation (55). Interestingly, diastolic strain rates, mea-
ured with color-coded tissue Doppler in subjects with
ron overload, appears to be related to the level of
xidative stress (56), indicating that these echocardio-
raphic parameters may be a surrogate for iron overload-
ase (HO)-1, but heme uptake overall still remains controversial. Non-heme iron
21), which is taken up by intestinal epithelium by the divalent metal transporter
iron carriers and later transported into the circulation by the duodenal iron
oxidized by ceruloplasmin in non-intestinal cells and also by a homolog of ceru-
the increase in intracellular concentrations of iron, ferritin synthesis also
ntracellularly in the form of hemosiderin and toxic nontransferrin-bound forms ofoxygen
ytes (
cell by
iron is
. With
ased induced oxidative stress (57).
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September 21, 2010:1001–12 Review on Iron Overload CardiomyopathyIt could be hypothesized that cardiac contractile reserve is
mpaired in IOC before detectable LV systolic dysfunction
ccurs at rest, and this abnormality might be detected by
tress echocardiography. We have tested this hypothesis in
symptomatic HH subjects, and found that contractile
eserve is not decreased in this population as compared with
ge- and sex-matched normal volunteers who lacked HH
utations (58). However, unexpectedly, a higher incidence
f ischemic stress electrocardiographic responses in HH
ubjects (33%) compared with normal subjects (10%) was
bserved. The significance of this finding is unclear, but
ighlights the necessity of stress echocardiography or other
tress imaging when evaluating coronary artery disease in
his population (58).
As a result of these considerations, echocardiography has
he potential to identify early pathophysiology due to iron
verload, although it is not sensitive enough to reveal actual
ron deposition in tissues. In addition, echocardiography has
een successfully employed to evaluate iron-depleting ther-
py in idiopathic hemachromatosis as it demonstrated a
ecrease in the LV mass and wall thickness, and these
ndings correlated with the reversal of myocardial iron
nfiltration (59).
omputed tomography (CT). CT scanning can identify
igh electron density iron in the organs (60,61), but its
ensitivity and specificity are poor with high false positive
ates associated with fibrosis (62), and it has a low sensitivity
or detecting the early stages of iron overload in tissues (63).
he clinical usefulness of this diagnostic method for IOC
as not been tested.
RI. MRI is the only presently available noninvasive
ethod with the potential to assess quantitatively myocar-
ial iron load. MRI constructs images from transmitted
icrowave signals induced by exciting protons in the body
n a high magnetic field. In noniron-overloaded hearts,
hese signals are homogenous, and relaxation time (time to
ade excited signals) lasts for a longer duration (brighter over
ime). In iron-overloaded hearts, however, the iron para-
agnetic effect produces changes in MR signal intensity
nd susceptibility, and shortens the relaxation time and
arkens the image more quickly (64). MRI scanning can
efocus the signals returning from the tissues, using a special
adiofrequency pulse (spin echo [SE]) or by using special
mall magnetic fields called gradients (gradient echo [GE])
t specific time intervals (echo time [TE]). The time
onstant of decay for SE-induced relaxation time is known
s T2 and for GE is T2*, and the units are in milliseconds
ms). Iron in the tissue shortens the relaxation time (signals
ade faster with more iron content), thus, the more the iron
ontent, the shorter are the T2 and T2*. Some investigators
eport rates of signal decay (R2 1,000/T2 and R2* 
,000/T2*), which are reciprocals of T2 and T2*, respec-
ively, and are measured in Hertz or s1. Earlier studies for
uantitative evaluation of the iron content were performed
sing the SE measurement, and it was noted to have an
nverse relation with liver iron concentration (65–67). SE tas a poor signal-to-noise ratio at longer echo times, and,
ith its limited sensitivity, is unsatisfactory to make the
ccurate quantification of myocardial iron (65,66,68,69).
n the other hand, GE techniques, which do not have these
roblems, seem to be more suitable for assessing myocardial
ron content. Anderson et al. (70) were the first to use the
2* technique for myocardial iron assessment in subjects
ith thalassemia major. In that study, a single short-axis
idventricular slice was acquired at 9 separate TEs, and
ach slice was acquired during 1 breath hold of approxi-
ately 20 s (Fig. 2). It was observed that there was a
rogressive decline in ejection fraction as the myocardial
ron deposition increased, and all patients with ventricular
ysfunction had a myocardial T2* of 20 ms (71). The
oefficient of variation for interstudy reproducibility of
ardiac T2* was 5%. The scanning time of T2* was recently
hortened by the use of a multi-GE technique that has the
dvantage that all slices are acquired in just 1 breath hold
72). Pepe et al. (73) used a multislice multi-GE T2*
echnique to achieve segmental analysis of LV myocardial
ron content and observed a good correlation between the
lobal T2* (12 segments) and T2* value in the midventricu-
ar septum. They concluded that the midventricular T2*
alue was a good marker of the entire myocardial iron
ontent. However, they were concerned that midventricular
2* would not be sensitive enough to reflect the heteroge-
eity of composition of myocardial iron overload (cytosolic
ron, hemosiderin deposits, and so on) (69,73–75). In
ontrast, the T1-/T2-weighted SE method has been pro-
osed as being more sensitive in differentiating cytosolic
ron and ferritin (76). Recent optimized breath-hold T2
maging has shown improved local interstudy reproducibil-
ty and intersite reproducibility, with coefficients of variance
f 4.4% and 5.2%, respectively, as compared with the
raditional T2* imaging (77). One potential advantage of
ewer T2 imaging will be to perform a multisegment
nalysis to explore regional distribution of myocardial iron.
he accuracy of T2* imaging is currently limited to the
eptum due to susceptibility effect artifacts from anterior
nd posterior cardiac veins and lungs that contaminate
mages of the other LV regional walls. In addition, measur-
ng both T2 and T2* might be beneficial, if different forms
f tissue iron might be respectively defined by T2 and T2*
easurements (77).
Furthermore, cardiac MRI can provide accurate repro-
ucible measures of LV systolic ejection fraction, volumes,
nd mass that can be followed over the course of therapy
78). A correlation between the decline in LV ejection
raction and higher myocardial iron content measured with
2* has been noted (79–81). Attempts to assess LV
iastolic function in IOC with cardiac MRI using tagging
82) or displacement encoding with stimulated echoes
DENSE) sequence (83) is currently under investigation.
In summary, GE T2* technique is still widely used for
linical assessment of entire iron content in IOC; however,
he new technical development of cardiac MRI will likely
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Review on Iron Overload Cardiomyopathy September 21, 2010:1001–12rovide methods for more detailed quantification and char-
cterization of deposited iron species in IOC.
roposed Clinical Pathway to Evaluate for IOC
s a result of our experience with patients with cardiomy-
pathy, we currently propose the following clinical pathway
o evaluate for IOC. This pathway is currently being used by
he National Institutes of Health Clinical Center Cardiol-
gy Consult Service (Fig. 3).
If the patient is known to be at risk for iron overload due
o a previous genetic diagnosis of HH or multiple RBC
ransfusions, transthoracic echocardiography with complete
V diastolic function assessment including tissue velocity
easurements of the mitral annulus should be conducted
very 1 to 2 years. This evaluation should occur regardless of
ardiac symptoms or biochemical evidence of iron overload.
f either abnormal LV diastolic function and/or decreased
eak systolic tissue velocity of mitral annulus are noted,
ardiac MRI with T2* assessment following the grading
ystem based on the T2* measurements listed in the follow-
ng text should be performed. In cases where idiopathic
ardiomyopathy is the primary diagnosis, regardless of iron
tudy results, we recommend cardiac MRI with T2* mea-
urements to rule out IOC since it has been reported to
ccur with normal iron levels (44,45) and is a treatable
ondition. Once cardiac T2* is confirmed to be normal
20 ms), it is unlikely that IOC will become a cause of
diopathic cardiomyopathy unless the patient is at risk for
OC and develops it in the future.
Figure 2 Typical Examples of T2* Cardiac MRI Imaging to Ass
T2* images were obtained by using the gradient echo sequence of cardiac magne
(70). The images captured at TE time of 5 ms are shown. T2* image of a 45-year
and heart (A; heart T2*  39 ms; liver T2*  27 ms). T2* image of a 35-year-old
load in both the liver (arrowhead) and heart (arrows) (B; heart T2*  12 ms; live
shows iron overload seen in the liver (arrowhead), but not heart (C; heart T2*  3
the images. (The images in this figure were provided by Andrew Arai, MD, Branch o
tutes of Health, Bethesda, Maryland.)onventional Therapy
ron overload is a slow, cumulative process; early diagnosis
nd treatment should be the main goal of therapy to prevent
ultiorgan failure. Standard treatment currently includes
ietary management, phlebotomy, and chelating agents. At
resent, research using calcium channel blockers (CCBs) in
OC, gene therapy to target the genetic mutations in
halassemia and sickle cell disease, and heart transplantation
n refractory heart failure are under intense scrutiny.
In order to assist with clinically grading the severity of
OC at this time, people at risk for IOC may be divided into
categories based on cardiac T2* values (64):
. Those with T2* 20 ms (green zone) are at low risk for
the imminent development of congestive heart failure.
. Those with T2* between 10 and 20 ms (yellow zone) in
whom cardiac deposition has probably occurred are at
intermediate risk of cardiac decompensation.
. Those with T2* 10 ms (red zone) are in the high-risk
category of cardiac decompensation and need immediate
review and intensification of chelation therapy.
Although the diagnostic use of cardiac MRI for IOC has
een established, the validity of T2* obtained from cardiac
RI as a therapeutic marker is still under investigation.
hus, proper guidelines to follow for evaluating the thera-
eutic effects of IOC treatment with cardiac MRI measure-
ents still need to be developed.
There is some evidence that with the use of effective
helation therapy, the development of clinically significant
ardiac iron overload in patients in the green and yellow
ones may be delayed (59,84,85). It is apparent that patients
oth Myocardial and Liver Iron Overload
onance imaging (MRI) employing a 1.5-T scanner as reported by Anderson et al.
th idiopathic cardiomyopathy (CM) shows no evidence of iron overload in the liver
le with sickle cell anemia and a history of multiple transfusions shows iron over-
 2 ms). T2* image of a 45-year-old male with hereditary hemachromatosis (HH)
; liver T2*  2 ms). Please note that iron-overloaded tissues appear darker in
iac Energetics, National Heart, Lung, and Blood Institute of the National Insti-ess B
tic res
-old wi
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reated with aggressive chelation therapy in conjunction with
tandard heart failure medications including angiotensin-
onverting enzyme inhibitors, diuretics, and beta-blockers.
t remains to be seen whether the addition of chelation
herapy will either stop the progression of or improve LV
ysfunction beyond what might be accomplished by aggres-
ive standard heart failure treatment.
ietary management. Dietary interventions to minimize
r eliminate iron ingestion are not feasible and are usually
nnecessary as only 0.5 to 1.0 mg of iron is absorbed daily
n excess of normal absorption in most persons with
emochromatosis, and the total daily absorption is small in
omparison with the 200 to 250 mg of iron per unit of blood
emoved weekly by therapeutic phlebotomy. Diets do not
nhance iron excretion, and patients must understand that
here is no substitute for iron depletion therapy (86).
atients can eliminate the consumption of iron-rich foods
uch as red meat and still have little effect on total body iron
ontent. Alcohol increases iron absorption and should be
inimized (87). Multivitamin tablets containing iron and
itamin C should be avoided (88). Tannates, phytates,
xalates, calcium, and phosphates present in food can bind
ron and inhibit its absorption, which provides little
enefit (89).
hlebotomy. Phlebotomy, the gold standard for treating
H, causes iatrogenic anemia by removing 400 to 500 ml of
lood (200 to 250 mg of iron) at each session, thus
Figure 3 Our Proposed Clinical Pathway to Evaluate Patients W
IOC  iron overload cardiomyopathy; LV  left ventricle; MRI  magnetic resonanobilizing iron from the organs where it is stored for the
roduction of hemoglobin. Early in the disease, this proce-
ure may be done up to 1 or 2 times a week to obtain a
arget ferritin below 20 ng/ml (90,91). Once the therapeutic
erritin level is achieved, the frequency of maintenance
hlebotomy is determined with periodic follow-up of serum
ron and ferritin levels with gradual decreasing phlebotomy
nterval. Generally, maintenance phlebotomy requires phle-
otomy 3 to 4 times a year for men and 1 to 2 times for
omen (92). Routine monitoring of hemoglobin, ferritin,
nd hematocrit is essential during maintenance phlebotomy
93). Improvements in cardiac function in HH patients with
ardiomyopathy and refractory arrhythmias have been noted
ith aggressive iron removal with phlebotomy, especially
hen started early in the disease process (94–96).
helating agents. Phlebotomy is not feasible in patients
ho have significant anemia or malignancy, and in some
ith hemodynamic instability. In such cases, chelation
herapy has been effectively used as an alternative. The goal
f chelation therapy is to detoxify those organs containing
xcess iron by binding the iron, removing it, and then
xcreting the compound in urine and bile. Presently avail-
ble chelators include deferoxamine, deferasirox, and
eferiprone.
Deferoxamine is a clinically approved, highly specific
exadentate iron-chelating molecule that binds to iron
eleased from the reticuloendothelial system, which has
cavenged iron after the catabolism of senescent RBC, and
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Review on Iron Overload Cardiomyopathy September 21, 2010:1001–12xcretes it in the urine. It also has a very high affinity to bind
ith the trivalent ferric ion and is thought to remove cardiac
ron by direct interaction with this ion. The benefits of
ong-term subcutaneous deferoxamine therapy of increasing
urvival and decreasing cardiac complications in transfusion-
ependent, iron-overloaded thalassemia patients is well docu-
ented in the medical literature (2,83,97,98). High intra-
enous doses, instead of traditional subcutaneous infusion,
re also used for the rapid removal of cardiac iron from
eavily iron-loaded patients with cardiac failure (84). Pro-
pective studies confirming the beneficial effect of intrave-
ous deferoxamine in the reduction of myocardial iron
ontent in IOC were reported in patients treated with
ntravenous deferoxamine for 12 months with MRI-derived
2* (99). Reduction in iron levels was associated with an
ncrease in T2* MRI values (5.1  1.9 ms to 8.1  2.8 ms,
lacebo vs. deferoxamine, p  0.003), significant improve-
ents in LV ejection fraction (52  7.1% to 63  6.3%,
 0.03), and reductions in LV volume and LV mass
ndex. Unfortunately, deferoxamine has a high maintenance
ost, poor oral bioavailability, and the need for frequent
dministration. These considerations often contribute to
oor compliance in patients (100).
Deferiprone is a bidentate chelating agent with good oral
ioavailability and rapid absorption from the stomach,
hich reaches peak levels in 2 h after administration after
eing metabolized in the liver. It is being tested on
-thalassemia and sickle cell patients with transfusion iron
verload, and its long-term efficacy and safety have not been
ully established (93). In the U.S., it is available only
hrough the Food and Drug Administration treatment use
rogram. Clinical efficacy of deferiprone is less consistent
han deferoxamine (101,102). In a randomized, double-
lind, placebo-controlled trial in 65 patients over 12
onths, subcutaneous deferoxamine combined with oral
eferiprone therapy reduced myocardial iron and improved
he ejection fraction and endothelial function in thalassemia
ajor patients with mild to moderate cardiac iron load
hen compared with deferoxamine therapy alone (103).
Deferasirox is a tridentate lipophilic oral chelating agent
hat selectively binds to iron in the ratio of 2:1 and mobilizes
ron from stores. The early benefit of using deferasirox has
een demonstrated in thalassemia, sickle cell disease, myo-
roliferative disorders, and Diamond-Blackfan anemia. Re-
ults from small-scale, randomized phase III trials evaluat-
ng the effect on iron overload have been encouraging
104,105). Despite these hopeful results, long-term safety
nd efficacy beyond 1 year is lacking at this time. Thus,
here are insufficient data at present to support the use of
eferasirox to treat IOC.
ewer chelating drugs. Deferitrin, desferrithiocin, hydroxy-
enzylethylenediamine-diacetic acid, pyridoxal isonicotinoyl
ydrazone, 2-pyridylcarboxaldehyde 2-thiophenecarboxyl hy-
razone, and L1NA-II (a deferiprone derivative) are among
he newer chelating agents that are under active investigation.drug with satisfactory oral bioavailability and good long- oerm efficacy and safety would be extremely useful, and a quest
or such an agent is ongoing.
rythrocytapheresis. Erythrocytapheresis involves an au-
omated exchange of RBCs of patients with hemachroma-
osis with those of subjects without and thus helps in
ecreasing the iron overload mainly in the form of hemo-
lobin (106,107). This procedure is mainly used in treat-
ent and prophylaxis of sickle cell patients by removing the
ickle cells and also old RBCs (107). This is a complex and
ostly procedure with a high risk of infection, and further
esearch is needed to prove its efficacy for IOC (108).
eart transplant. If a patient has reached stage IV New
ork Heart Association functional class heart failure symp-
oms without any improvement in heart failure despite
ggressive medical therapy including cardiac resynchroniza-
ion therapy, heart transplantation may be a reasonable
ption to extend survival and improve quality of life. If heart
ransplantation becomes a serious consideration, it must be
erformed in combination with the aggressive application of
herapy to reduce iron overload. Recently, Caines et al.
109) published a review of 16 IOC end-stage heart failure
atients who received heart transplantation from 1967 to
003, with a mean age of 31 years (age range 14 to 63 years).
hey had a actuarial 10-year survival rate of 41% with
aplan-Meier analysis, with 1-, 3-, and 5-year survival rates
f 81% for all 3 time intervals (109). Three patients died
ithin 1 year secondary to infectious complications. Thirty-
ay mortality was 12% (109). When severe IOC and hepatic
ron overload coexist, combined heart-liver transplantation
ay be considered because transplantation of only a single
rgan might not improve the outcome (109). There are a
imited number of cases available in the literature, and thus
ore data are needed to validate whether heart transplan-
ation actually improves the clinical outcome of patients
hort and long term.
ewer Mechanistic Directed Therapeutic Options
ole of CCBs. The mechanisms of iron transport into
xcitable tissues such as cardiac myocytes are under active
nvestigation. Non–transferrin-bound iron enters the heart
n the ferrous form, and the rate of transport increases with
ugmentation of the iron load (110). Recent evidence has
uggested that voltage-gated LTCC may be involved with
ron transport into cardiomyocytes. LTCC primarily trans-
ort Ca2, but can also transport other divalent ions such as
e2 and Zn2 (24,111). The association of LTCC with
ron uptake is evident in studies that have shown: 1) an
ncrease in iron uptake rates in excitable tissues, i.e., tissues
ith pacemaker qualities, compared with nonexcitable tis-
ues as they have more LTCC (110,111); 2) an increased
ctivity of LTCC with increased levels of iron (111–114);
nd 3) LTCC agonist Bay K 8644 produced a 2.3-fold
ncrease in the nifedipine-sensitive Fe2 uptake by the heart
y enhancing LTCC activity (24). More definitive evidence
f the role of LTCC in iron overload was found when Oudit
e
v
d
L
m
s
t
t
L
o
c
t
p
(
I
s
p
t
c
b
t
s
D
o
H
c
a
l
t
w
t
h
l
h
b
r
e
s
i
z
t
r
t
l
p
l
a
s
m
u
h
h
d
f
l
r
u
r
R
s
t
I
d
w
t
p
o
s
t
h
t
m
a
(
h
d
o
p
w
p
a
A
t
r
s
c
T
R
i
c
d
r
r
h
b
t
a
l
d
c
b
C
I
d
i
i
c
f
t
1009JACC Vol. 56, No. 13, 2010 Gujja et al.
September 21, 2010:1001–12 Review on Iron Overload Cardiomyopathyt al. (114) used therapeutic levels of the LTCC blockers
erapamil and amlodipine to treat IOC in mice, and
emonstrated that treatment with CCBs inhibited the
TCC current in cardiac myocytes, thereby attenuating
yocardial iron accumulation and oxidative stress, improved
urvival, prevented hypotension, and preserved heart struc-
ure and function. It was also noted that iron-overloaded
ransgenic mice with cardiac-specific overexpression of the
TCC 1-subunit had 2-fold higher myocardial iron and
xidative stress levels, as well as greater impairment in
ardiac function. LTCC blockade in these mice protected
hem from iron overload. The above findings indicate the
ossible preventive and therapeutic roles of CCBs in IOC
114). If effective, they may be used in the early stages of
OC, and may also enhance the therapeutic effects of
tandard chelation therapy. The role of verapamil, but
erhaps not the dihydropyridine CCBs, may be limited in
he advanced stage of IOC, which may be associated with
onduction system defects and LV systolic dysfunction,
oth of which may be exacerbated by verapamil administra-
ion. Presently, a nonrandomized, open-label trial spon-
ored by the National Institute of Diabetes and Kidney
isease is underway to assess the role of nifedipine in iron
verload patients.
epcidin. The human hepcidin gene HAMP located on
hromosome 19 encodes for a precursor protein, 84-amino
cid preprohepcidin, which is primarily produced in the
iver. It undergoes subsequent post-translational processing
hat results in a mature 25-amino acid form, hepcidin,
hich plays a major role in regulating iron homeostasis in
he body. The evidence for this conclusion was observed in
epcidin knockout mice that developed massive iron over-
oad (115) as well as in mice engineered to overproduce
epcidin who developed severe anemia (116). Hepcidin
inds to ferroportin, resulting in internalization and deg-
adation of ferroportin, thereby blocking cellular iron
xport (117,118). This obstruction results in a decrease in
erum iron levels by blocking iron absorption from the
ntestine, iron recycling from macrophages, and mobili-
ation of stored iron from liver hepatocytes. Hepcidin is
hought to be regulated by hemojuvelin, transferrin
eceptor-2, transferrin, the HFE gene, hypoxia, inflamma-
ion, and erythroid factors (119). Besides production by the
iver, hepcidin is also believed to be produced by macro-
hages (120), fat cells (121), and the heart (122). Lower
evels of hepcidin were observed in studies on HH (123,124)
nd nonhemachromatosis iron overload diseases (125–127),
o hepcidin analysis might provide a role in screening,
onitoring, prognosis, and therapy of HH. Techniques
sing mass spectrometry can identify various isoforms of
epcidin in urine and serum (128,129). Augmentation of
epcidin levels by iron reduction, hepcidin inducers, hepci-
in supplements, and antioxidants may play a role in the
uture treatment of iron overload conditions. There is still a
ot to understand about the full potential of this key
egulator of iron homeostasis, and additional studies are anderway and are needed to determine its role in iron
egulation.
ole of gene therapy. Curing primary genetic diseases
uch as -thalassemia and sickle cell disease before or after
issues develop iron overload could be an option to prevent
OC. Gene therapy involves correction of the underlying
efect by genetically modulating autologous stem cells,
hich are then implanted by a vector into the target cell,
hereby facilitating the expression of the desired functional
roduct by the target cells. Lentiviral vectors proved capable
f efficiently transmitting complex globin expression cas-
ettes containing transcriptional regulatory sequences from
he -globin locus control region, which are required for
igh-level expression, to treat -thalassemia (130). Correc-
ion of anemia and organ damage in -thalassemic mouse
odels has been achieved using both -globin (131,132)
nd -globin vectors (133,134). Recently, Pestina et al.
130) reported the use of a -globin lentiviral vector for
ematopoietic stem cell transduction in severe sickle cell
isease. Similar gene therapy approaches designed to target
verexpression of hepcidin and inhibition of DMT-1 ex-
ression, ferroportin expression, and expression of the
ild-type HFE gene using duodenal stem cells have been
ostulated to greatly reduce the iron accumulation in HH
nd are yet to be evaluated in mouse models of HH (135).
lthough the approach of gene therapy is promising, these
echniques have relatively high morbidity and mortality
ates, and extensive biosafety research is needed to demon-
trate that the benefit-to-safety ratio is acceptable before it
an be accepted as a mainstream medical treatment of IOC.
hese studies are presently being pursued.
ole of stem cell transplantation. It is also hoped that
ntroduction of healthy hematopoietic stem cells in severe
ongenital anemia lacking appropriate -hemoglobin pro-
uction, such as sickle cell disease or -thalassemia, may
everse the primary pathophysiology in the disease and
educe the need for transfusions (136). This approach,
owever, presently is not ready for widespread application
ecause stem cell transplantation requires aggressive chemo-
herapy and radiation unless perfectly matched donor cells
re available. Currently, clinical trials are underway to test
ow-intensity radiation along with immunosuppressant
rugs without chemotherapy to accomplish successful stem
ell transplantation with a half-matched donor in order to
roaden its use.
onclusions
OC is a potentially lethal, but treatable disease when
iagnosed and treated early in its course. Newer insights
nto iron homeostasis and the complicated mechanism of
ron entry into the heart are now emerging. Improved
ardiac imaging techniques are being developed and per-
ected for the early identification of iron overload and its
reatment. New therapeutic options with better chelating
gents with increased safety, efficacy, and absorption, with
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CBs, hepcidin, and genetic and stem cell therapy are being
nvestigated and may play a role in future disease manage-
ent. Further studies are needed to define optimal medical
are for increasing survival and improving quality of life for
hese patients. In the interim, it is important to use the
echniques presently available for early diagnosis and to
tilize the existing therapeutic interventions in a safe
anner.
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